Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700464 · ClinicalTrials.gov registry record · NA
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
A NA study of Bladder Cancer, sponsored by Nucleix.
- Completed
- Registry status
- NA
- Development phase
- 680
- Enrollment target
- 11
- Study locations
NCT02700464: Completed NA study of Bladder Cancer, sponsored by Nucleix.
NCT02700464 is a NA study of Bladder Cancer that has completed, run by Nucleix. The registered enrollment target is 680 participants, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (95% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02700464, a NA study of Bladder Cancer, has completed, sponsored by Nucleix.
- COMPLETED
- Registry status
- NA
- Development phase
- 680 participants
- Enrollment target
- 11
- Study locations
Study Summary
Clinical trial to determine the efficacy (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of bladder cancer.
Conditions Studied
Interventions
- DEVICE Bladder EpiCheck Urine Test
- PROCEDURE Cystoscopy and pathology
Study Locations (11)
Colorado
- The Urology Center of Colorado - Denver
Maryland
- Chesapeake Urology Research Associates - Baltimore
Michigan
- Michigan Institute of Urology, P.C. - Troy
Minnesota
- Metro Urology - Woodbury
New York
- Urological Surgeons of Long Island - Garden City
North Carolina
- Duke University Health System - Durham
Ohio
- Cleveland Clinic - Cleveland
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2016-09 |
| Est. Completion | 2020-07 |
| Phase | NA |
What the finished NCT02700464 record still lists
NCT02700464 is an interventional study that assigns participants to a tested intervention. The registered 680 participants enrollment target is mid-sized for trials with a published cap, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bladder EpiCheck Urine Test is the first listed.
NCT02700464 lists 11 locations in 11 states (Colorado, Maryland, Michigan).
Frequently Asked Questions
What is clinical trial NCT02700464 about?
NCT02700464 is a clinical study titled "The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma". Clinical trial to determine the efficacy (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients under monitoring for recurrence of bladder cancer.
What is the current status of trial NCT02700464?
This trial is currently completed. It is a NA study. The enrollment target is 680 participants. The study started on 2016-09. Estimated completion is 2020-07.
What conditions does trial NCT02700464 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT02700464?
The interventions under investigation include: Bladder EpiCheck Urine Test (DEVICE), Cystoscopy and pathology (PROCEDURE).
Who is sponsoring clinical trial NCT02700464?
This trial is sponsored by Nucleix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02700464 being conducted?
This trial has 11 study locations across Colorado, Maryland, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02700464's enrollment target sits among peer trials
680 24th of 175 higher than 152 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia